Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Thioredoxin-loaded nanocomposite wound dressing for the delivery of adipose derived stem cells for wound healing applications.

Yang J., Zhang Z., Jing L., Ge J., Deng D.

Animal Study on Chronic Wound, Immune Modulation, published in J Biomater Appl (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Biomater Appl (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
40293717
DOI
10.1177/08853282251336554

Abstract (original English)

In the current research, Thioredoxin was loaded into chitosan nanoparticles and then loaded into the matrix of collagen hydrogel containing adipose-derived stem cells (ASCs). In vitro studies including Scanning electron microscopy imaging, cell viability assay, cell migration assay, swelling assay, release assay, radical scavenging assay were performed in order to characterize the dressings. Then, the wound healing activity of these scaffolds were studied in a rat model of wound healing. Our findings indicate that the scaffolds markedly accelerated wound closure, enhanced epithelial regeneration, and increased collagen deposition. The wound closure values for the developed dressings were 60.507 ± 2.287% on Day 7 and 95.270 ± 2.600% on Day 14. ELISA results demonstrated an upregulation of VEGF, b-FGF, and TGF-β expression, while TNF-α and IL-6 levels were significantly reduced. For our developed dressings, VEGF levels were 661.307 ± 80.195 pg/mL, while bFGF was detected at 524.410 ± 81.040 pg/mL. The concentration of TGF-β was 315.357 ± 54.783 pg/mL, and TNF-α was measured at 176.093 ± 43.934 pg/mL. Additionally, IL-6 levels were found to be 187.577 ± 40.860 pg/mL. Our results suggest that our developed hydrogel system has improved wound healing via improving angiogenesis and modulating inflammation. These mechanisms can be attributed to the proangiogenic and immunomodulatory ac

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsWound HealingRatsChitosanAdipose TissueNanocompositesStem CellsBandagesMaleHydrogels

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research